Skip to content

Prime Medicine PRME Increase (Decrease) in Prepaid Expense and Other Assets

Increase (Decrease) in Prepaid Expense and Other Assets at other companies

Intellia Therapeutics logo
Intellia TherapeuticsNTLA
$12.97M+6,050%
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
$247K-61.0%
Beam Therapeutics logo
Beam TherapeuticsBEAM
$31.86M+65,122%
Sana Biotechnology logo
Sana BiotechnologySANA
-$1.63M-19.0%
Eli Lilly logo
Eli LillyLLY
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX

Other financials

Income statement

See full
Revenue$838.0K-61.6%
Operating income-$50.7M+3.3%
Net income-$49.1M+5.3%
EPS (diluted)-$0.28+30.0%

Balance sheet

See full
Cash & equivalents$77.8M-26.6%
Total debt$114.5M-5.5%
Total equity$76.7M-28.3%
Total assets$294.7M-10.2%

Cash flow

See full
Operating cash flow-$42.7M+12.6%
CapEx$214.0K-91.2%
Free cash flow-$42.9M+16.3%

Valuation

See full
Market cap$574.36M+111%
Enterprise value$611.08M+113%
P/S124×+6.3×

Profitability

See full
Operating margin-4,498.1%-1,134pp
Net margin-4,342.4%-1,099pp
FCF margin-3,607.4%

Returns & leverage

See full
Return on equity-216.1%+1,519pp
Debt / equity1.5×+0.4×
Current ratio3.8×-1.0×

Where this comes from

Reported directly by Prime Medicine in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets.

The official record: Prime Medicine’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Prime Medicine's increase (decrease) in prepaid expense and other assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Prime Medicine's increase (decrease) in prepaid expense and other assets?
Prime Medicine (PRME) reported increase (decrease) in prepaid expense and other assets of -$1.22M in Q1 2026.
How has Prime Medicine's increase (decrease) in prepaid expense and other assets changed year-over-year?
Prime Medicine's increase (decrease) in prepaid expense and other assets decreased by 254.8% year-over-year, from $789K to -$1.22M.
What is the long-term trend for Prime Medicine's increase (decrease) in prepaid expense and other assets?
Over 3 years (2022 to 2025), Prime Medicine's increase (decrease) in prepaid expense and other assets has grown at a 37.8% compound annual growth rate (CAGR), from $1.74M to -$4.55M.
What does increase (decrease) in prepaid expense and other assets mean?
This tracks changes in cash paid in advance for goods or services that will be consumed in future periods. It reflects the timing difference between cash outflows and the recognition of related expenses on the income statement.